Two Long-Established Independent IRBs Discussing Merger
Independent Review Consulting (IRC) an independent Institutional Review Board (IRB) founded in 1984 announced that it has entered into a preliminary agreement to merge with the Ethical Review Committee (ERC), another central IRB providing reviews of research on behalf of subject safety since 1988. Erica Heath, founder of Independent Review Consulting (IRC), accredited by the Association for the Accreditation of Human Research Protection Program, Inc. (AAHRPP) and located in Northern California is in talks with Terri Majors, President of the Ethical Review Committee (ERC) in Missouri. Under the terms of the proposed merger, the two organizations will begin implementing an integration plan immediately while they continue to operate as their respective organizations. The first phase of the plan will be the formation of Ethical and Independent Review Services (E&I), a new Limited Liability Corporation to provide management services for both entities. Both companies have experience in the review of late-stage, multi- center trials. While IRC specializes in medical devices and federally funded studies, ERC has developed processes specializing in efficient turn-around of large, late-stage multi-center trials.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
